Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NYSE American - Delayed Quote USD

OS Therapies Incorporated (OSTX)

Compare
1.3100
+0.0600
+(4.80%)
At close: April 14 at 4:00:00 PM EDT
1.3200
+0.01
+(0.76%)
After hours: April 14 at 7:56:07 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for OSTX

Recent News: OSTX

View More
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
Business Wire 4 days ago
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals
Business Wire 5 days ago
OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma

OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma
Business Wire 7 days ago
OS Therapies to Host Analyst Day at NYSE on April 7, 2025

OS Therapies to Host Analyst Day at NYSE on April 7, 2025
Business Wire 12 days ago
OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update

OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update
Business Wire 14 days ago
OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma

OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma
Business Wire 14 days ago
OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers

OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
Business Wire 20 days ago
OS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to Analysts

OS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to Analysts
Insider Monkey 22 days ago
OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference

OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference
Business Wire 24 days ago
OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference

OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
Business Wire last month
OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma
Business Wire last month
View More

Related Tickers

ELDN Eledon Pharmaceuticals, Inc.
2.9800
+1.36%
 
THAR Tharimmune, Inc.
1.1745
+4.87%
 
FBLG FibroBiologics, Inc.
0.9800
+10.11%
 
GLMD Galmed Pharmaceuticals Ltd.
1.3300
+0.76%
 
BDRX Biodexa Pharmaceuticals Plc
1.6500
-6.78%
 
CERO CERo Therapeutics Holdings, Inc.
0.6710
-4.13%
 
BCLI Brainstorm Cell Therapeutics Inc.
0.7761
+1.80%
 
OSRH OSR Holdings, Inc.
1.5800
+9.72%
 
ONCO Onconetix, Inc.
0.0696
+11.72%
 
ELAB PMGC Holdings Inc.
3.1800
+3.58%